{
    "clinical_study": {
        "@rank": "33534", 
        "acronym": "PACER", 
        "arm_group": {
            "arm_group_label": "adriamycin,cytoxan, cisplatin", 
            "arm_group_type": "Experimental", 
            "description": "4 cycles of Adriamycin 60 mg/m2 and Cyclophosphamide 600 mg/m2 every 3 weeks followed by 4 cycles of cisplatin 75 mg/m2 every 3 weeks"
        }, 
        "brief_summary": {
            "textblock": "Achievement of pathologic complete response is important prognosticator to predict long term\n      outcome in triple negative cancer. The efficacy of  adding 4 cycles of cisplatin (CDDP4) is\n      to be investigated whether addtional pathologic complete response is achieved for those\n      triple negative breast cancer patients who recieved 4 cycles of adriamycin with\n      cyclophosphamide(AC4) but did not reach clinical complete response during the course of\n      neoadjuvant therapy."
        }, 
        "brief_title": "Additional 4 Cycles of Cisplatin (CDDP4) in Patients With Triple Negative Breast Cancer for Neoadjuvant Chemotherapy", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "First outcome measures (analysis) :at the time of surgery,\n\n      Second outcome measures:\n\n      2019 August, 5 year Overall Survival, Disease free survival"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients with histologically proven breast cancer\n\n          2. Age, at least 20  years\n\n          3. ER/PR/HER2 (negative/negative/negative\n\n               -  ER/PR negative: nuclear reaction < 1%, Allred score 0 or 2\n\n               -  HER2 negative: HER2; IHC (immunohistochemistry) 0,1+ or FISH/SISH (-) in case of\n                  IHC 2+\n\n          4. Clinically stage II or III with histologically proven lymph-node involvement (T >1.5\n             cm or lymph node [LN] >1.5 cm)\n\n          5. Eastern  Cooperative Oncology Group (ECOG) performance status 0 or 1\n\n          6. No prior hormonal treatment, chemotherapy or radiotherapy is allowed.\n\n          7. Adequate hematologic, liver and kidney function\n\n          8. Written informed consent\n\n        Exclusion Criteria:\n\n          1. Pregnancy or lactation\n\n          2. Prior chemotherapy or radiotherapy for any malignancy\n\n          3. Stage T4d; inflammatory breast cancer\n\n          4. No primary tumor (T0)\n\n          5. Documented history of cardiac disease contraindicating anthracyclines\n\n          6. Currently active infection"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "88", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02001519", 
            "org_study_id": "TNBC AC-CDDP"
        }, 
        "intervention": {
            "arm_group_label": "adriamycin,cytoxan, cisplatin", 
            "description": "4 cycles of Adriamycin 60 mg/m2 and Cyclophosphamide 600 mg/m2 every 3 weeks 4 cycles of cisplatin 75 mg/m2 every 3 weeks", 
            "intervention_name": "AC4-CDDP4", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cisplatin", 
                "Cyclophosphamide", 
                "Doxorubicin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 28, 2013", 
        "location": {
            "contact": {
                "email": "sbkim3@amc.seoul.kr", 
                "last_name": "Sung-Bae Kim, MD., Ph D.", 
                "phone": "82-2-3010-3210"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "138-736"
                }, 
                "name": "Asan Medical Center"
            }, 
            "investigator": {
                "last_name": "Sung-Bae Kim, MD., Ph D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase ll Trial of Impact of Additional 4 Cycles of Cisplatin (CDDP4) in Patients With Triple Negative Breast Cancer Not Achieving Clinical CR After 4 Cycles of Neoadjuvant Adriamycin Plus Cyclophosphamide", 
        "overall_contact": {
            "last_name": "Sung-Bae Kim, MD., Ph D.", 
            "phone": "82-2-3010-3210"
        }, 
        "overall_official": {
            "affiliation": "Asan Medical Center", 
            "last_name": "Sung-Bae Kim", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Rate of pCR (as defined by NSABP [National Surgical Adjuvant Breast and Bowel Project] criteria - absence of invasive disease in the breast [ypT0]) at the time of surgery.", 
            "measure": "pathologic complete response (pCR) rate", 
            "safety_issue": "No", 
            "time_frame": "up to 36 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02001519"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Asan Medical Center", 
            "investigator_full_name": "Sung-Bae Kim", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "after completion of chemotherapy Overall objective clinical response rate = CR (complete response) + PR (partial response) rate, measured by US (or MRI) and assessed by Response Evaluation Criteria in Solid Tumors (RECIST)", 
                "measure": "Overall response rate (ORR) by radiologic evaluation", 
                "safety_issue": "No", 
                "time_frame": "up to 36 weeks"
            }, 
            {
                "description": "after 2 cycles of AC", 
                "measure": "Complete metabolic response (CMR) rate after 2 cycles of AC", 
                "safety_issue": "No", 
                "time_frame": "up to 12 weeks"
            }, 
            {
                "measure": "3 year disease free survival (3yr-DFS)", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "after surgery", 
                "measure": "Rate of breast conservation", 
                "safety_issue": "No", 
                "time_frame": "up to 36 weeks"
            }
        ], 
        "source": "Asan Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Asan Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}